Media Summary: This workshop focused on common issues seen in abbreviated new drug applications (ANDAs), link GDUFA CDER Director Dr. Janet Woodcock explains how regulatory Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory
Fda Lecture Advancing The Science - Detailed Analysis & Overview
This workshop focused on common issues seen in abbreviated new drug applications (ANDAs), link GDUFA CDER Director Dr. Janet Woodcock explains how regulatory Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory Robert Lionberger, PhD, Director for the Office of Regulatory Included in this area of study are regenerative medicine, individualized and precision medicine, and examination of the ...
